Mayo Clinic Researchers Discover New Immunotherapy Target for Ovarian Cancer

Researchers at the Mayo Clinic Comprehensive Cancer Center have identified a new immunotherapy target that could significantly enhance treatment outcomes for patients with ovarian cancer. Published in Science Advances, the study highlights the potential of cryptic antigens—previously hidden protein fragments found in tumor cells—as key drivers in mobilizing the immune system against cancer.

Ovarian cancer remains one of the most challenging forms of cancer to detect and treat due to its subtle early symptoms and aggressive progression. Traditional immunotherapies, including checkpoint inhibitors, have shown limited effectiveness in treating the disease at advanced stages.

Unlocking Cryptic Antigens

The research team, led by Dr. Marion R. Curtis, an immunologist at Mayo Clinic, has focused on cryptic antigens, which are segments of proteins (known as epitopes) that are typically concealed from immune system detection. These antigens, once identified and targeted, can activate T cells, the body's immune defenders, to recognize and destroy cancerous cells.

“These findings underscore the need to look at alternate sources of target antigens for ovarian cancer,” said Dr. Curtis. “Discovering tumor-associated antigens that T cells recognize is crucial for the success of immunotherapeutic approaches in ovarian cancer, where the disease tends to grow aggressively and compromise healthy tissue.”

Advanced Multi-Omics Strategy

The study employed a multi-omics approach, integrating data from genomics, proteomics, microbiomics, and epigenomics to uncover new tumor-associated antigens. This comprehensive methodology allowed researchers to better understand the molecular and immunological landscape of ovarian cancer and identify promising targets for future therapies.

Moving Beyond Neoantigens

While prior research has focused heavily on neoantigens—newly formed proteins from mutated genes—these are rarely found in ovarian cancer, limiting their viability as therapeutic targets. The Mayo Clinic team’s shift toward cryptic antigens opens new possibilities for developing customized vaccines and T-cell therapies.

Future Steps

The next phase of the research will involve preclinical testing and clinical trials to assess the safety and effectiveness of treatments based on cryptic antigen targeting. Additionally, researchers plan to explore the expression of these antigens in other cancer types to evaluate broader applications of this strategy.

This discovery marks a pivotal advancement in ovarian cancer research, offering hope for more effective and targeted immunotherapy treatments in the near future.